Why the study?
Does the radioimmunoassay for human cardiac myosin light chain I differentiate between patients with and without myocardial infarction?
Does the radioimmunoassay for human cardiac myosin light chain I differentiate between patients with and without myocardial infarction?
A newly developed radioimmunoassay for human cardiac myosin light chain I provides a sensitive and specific marker for myocardial damage, significantly differentiating patients with and without myocardial infarction.
Light chain I elevation was associated with MI; leaves open diagnostic utility pending prospective validation.
A double-antibody radioimmunoassay that specifically measures serum or urinary concentrations of human cardiac myosin light chains has been developed. The assay is both sensitive and specific for myosin light chain I. The antiserum used in the assay is capable of detecting 1--2 ng/ml of cardiac myosin light chain I and shows no cross-reaction to cardiac myosin, the heavy chains of myosin, actin, tropomyosin, or light chain II. Of 114 patients admitted to the Coronary Care Unit, 227 measurements obtained from 84 patients without myocardial infarction revealed that the serum light chain level of 2.0 +/- 0.18 ng/ml was not significantly different from that of a control group (2.1 +/- 0.17 ng/ml, n = 12). In contrast, 89 measurements from 30 patients with myocardial infarction evidence clinically, electrocardiographically, and by creatine phosphokinase determinations were found to have an average serum light chain I concentration of 10.9 +/- 1.39 ng/ml (P less than 0.001). Thus, the radioimmunoassay for human cardiac myosin light chain I provides a sensitive and specific marker for myocardial damage.
No takes yet. Share an insight, caveat, or question.
Gere et al. (1979) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: